JP2020516651A5 - - Google Patents

Download PDF

Info

Publication number
JP2020516651A5
JP2020516651A5 JP2019555899A JP2019555899A JP2020516651A5 JP 2020516651 A5 JP2020516651 A5 JP 2020516651A5 JP 2019555899 A JP2019555899 A JP 2019555899A JP 2019555899 A JP2019555899 A JP 2019555899A JP 2020516651 A5 JP2020516651 A5 JP 2020516651A5
Authority
JP
Japan
Prior art keywords
stable
approximately
preparation according
formulation
mpa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019555899A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020516651A (ja
JP7398958B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/027166 external-priority patent/WO2018191414A1/en
Publication of JP2020516651A publication Critical patent/JP2020516651A/ja
Publication of JP2020516651A5 publication Critical patent/JP2020516651A5/ja
Priority to JP2023126162A priority Critical patent/JP2023139290A/ja
Application granted granted Critical
Publication of JP7398958B2 publication Critical patent/JP7398958B2/ja
Priority to JP2025119640A priority patent/JP2025148539A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019555899A 2017-04-11 2018-04-11 安定的抗ｏｓｍｒ抗体製剤 Active JP7398958B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023126162A JP2023139290A (ja) 2017-04-11 2023-08-02 安定的抗ｏｓｍｒ抗体製剤
JP2025119640A JP2025148539A (ja) 2017-04-11 2025-07-16 安定的抗ｏｓｍｒ抗体製剤

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762484260P 2017-04-11 2017-04-11
US62/484,260 2017-04-11
US201762524927P 2017-06-26 2017-06-26
US62/524,927 2017-06-26
PCT/US2018/027166 WO2018191414A1 (en) 2017-04-11 2018-04-11 Stable anti-osmr antibody formulation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023126162A Division JP2023139290A (ja) 2017-04-11 2023-08-02 安定的抗ｏｓｍｒ抗体製剤

Publications (3)

Publication Number Publication Date
JP2020516651A JP2020516651A (ja) 2020-06-11
JP2020516651A5 true JP2020516651A5 (https=) 2021-05-20
JP7398958B2 JP7398958B2 (ja) 2023-12-15

Family

ID=62111204

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019555899A Active JP7398958B2 (ja) 2017-04-11 2018-04-11 安定的抗ｏｓｍｒ抗体製剤
JP2023126162A Withdrawn JP2023139290A (ja) 2017-04-11 2023-08-02 安定的抗ｏｓｍｒ抗体製剤
JP2025119640A Pending JP2025148539A (ja) 2017-04-11 2025-07-16 安定的抗ｏｓｍｒ抗体製剤

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023126162A Withdrawn JP2023139290A (ja) 2017-04-11 2023-08-02 安定的抗ｏｓｍｒ抗体製剤
JP2025119640A Pending JP2025148539A (ja) 2017-04-11 2025-07-16 安定的抗ｏｓｍｒ抗体製剤

Country Status (11)

Country Link
US (5) US10493149B2 (https=)
EP (1) EP3609916A1 (https=)
JP (3) JP7398958B2 (https=)
KR (2) KR20200014738A (https=)
CN (2) CN110662761B (https=)
AU (2) AU2018251808B2 (https=)
BR (1) BR112019021364A2 (https=)
CA (1) CA3061705A1 (https=)
MA (1) MA53466A (https=)
MX (2) MX2019012255A (https=)
WO (1) WO2018191414A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE056580T2 (hu) 2013-05-30 2022-02-28 Kiniksa Pharmaceuticals Ltd Onkosztatin-M-receptor antigénjét kötõ fehérjék
JP5954916B1 (ja) 2015-04-14 2016-07-20 中外製薬株式会社 Ｉｌ−３１アンタゴニストを有効成分として含有する、アトピー性皮膚炎の予防用及び／又は治療用医薬組成物
KR20210096640A (ko) * 2018-11-29 2021-08-05 하버 바이오메드 테라푸틱스 리미티드 항-pd-l1 항체 제제
MX2022005654A (es) 2019-11-20 2022-06-22 Chugai Pharmaceutical Co Ltd Preparacion que contiene anticuerpo.
TWI904261B (zh) 2020-10-19 2025-11-11 美商碩騰服務公司 犬及貓抑瘤素Ｍ受體β之抗體及其用途
CN113274494B (zh) * 2021-06-07 2022-09-20 武汉生物制品研究所有限责任公司 一种抗SARS-CoV-2的重组全人源单克隆抗体的液体制剂

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA912136B (en) * 1990-03-29 1992-11-25 Bristol Myers Squibb Co Anti-oncostatin m monoclonal antibodies
EP1888637A2 (en) * 2005-05-19 2008-02-20 Amgen Inc. Compositions and methods for increasing the stability of antibodies
AR060487A1 (es) * 2006-04-21 2008-06-18 Xoma Technology Ltd Composiciones farmaceuticas de antagonistas del anticuerpo anti- cd40
AR080428A1 (es) 2010-01-20 2012-04-11 Chugai Pharmaceutical Co Ltd Formulaciones liquidas estabilizadas contentivas de anticuerpos
EP3409289B1 (en) * 2010-02-26 2020-09-30 Novo Nordisk A/S Stable antibody containing compositions
US8883979B2 (en) * 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
HUE056580T2 (hu) * 2013-05-30 2022-02-28 Kiniksa Pharmaceuticals Ltd Onkosztatin-M-receptor antigénjét kötõ fehérjék
TWI694836B (zh) * 2014-05-16 2020-06-01 英商葛蘭素史克智慧財產管理有限公司 抗體調配物
BR112019018022A2 (pt) 2017-03-01 2020-06-02 Medimmune Limited Formulações de anticorpos monoclonais

Similar Documents

Publication Publication Date Title
JP2020516651A5 (https=)
US11612659B2 (en) Anti-CD40 antibody formulation delivery device
US20250114449A1 (en) Stable anti-osmr antibody formulation
HK40109865A (zh) 稳定的抗osmr抗体制剂
HK40023281A (en) Lyophilised and aqueous anti-cd40 antibody formulations
HK1202050B (en) Lyophilised and aqueous anti-cd40 antibody formulations